Výsledky vyhledávání - "Paola Venturino"

Akademický článek

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

Autor: Antonio Marchetti, Maela Del Grammastro, Lara Felicioni, Sara Malatesta, Giampaolo Filice, Irene Centi, Tommaso De Pas, Armando Santoro, Antonio Chella, Alba Ariela Brandes, Paola Venturino, Franco Cuccurullo, Lucio Crinò, Fiamma Buttitta

Publikováno v: PLoS ONE, Vol 9, Iss 8, p e103883 (2014)

Assessment of EGFR mutation in non-small cell lung cancer (NSCLC) patients is mandatory for optimization of pharmacologic treatment. In this respect, mutation analysis of circulating tumor cells (CTCs) may be desirable since they may provide real-tim

Externí odkaz: https://doaj.org/article/871b39a4a9684627b9d7dadb6e4e450b

Zobrazit plný text záznamu

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment

Autor: Lara Felicioni, Armando Santoro, Giampaolo Filice, Tommaso De Pas, Lucio Crinò, Irene Centi, Paola Venturino, Sara Malatesta, Alba A. Brandes, Fiamma Buttitta, Antonio Marchetti, Antonio Chella, Franco Cuccurullo, Maela Del Grammastro

Publikováno v: PLoS ONE, Vol 9, Iss 8, p e103883 (2014)
PLoS ONE

Introduction Assessment of EGFR mutation in non-small cell lung cancer (NSCLC) patients is mandatory for optimization of pharmacologic treatment. In this respect, mutation analysis of circulating tumor cells (CTCs) may be desirable since they may pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2d0e55e71cbd31b325ae6c849437ad
http://europepmc.org/articles/PMC4138040?pdf=render

Zobrazit plný text záznamu

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

Autor: Luigi Mariani, Erminia Ferrario, Katia Fiorella Dotti, Arpine Gevorgyan, Maria Di Bartolomeo, Emilio Bajetta, Paola Venturino, Margherita Galassi, Roberto Bajetta, Roberto Buzzoni

Publikováno v: Cancer chemotherapy and pharmacology. 64(1)

This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients.Five dose level combinations with irinotecan (fr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::619f4e3ed91850ecaa7152e43568aba7
https://pubmed.ncbi.nlm.nih.gov/18936940

Zobrazit plný text záznamu

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy

Autor: Ornella Belvedere, Alba A. Brandes, Paola Venturino, Domenico Amoroso, Marcello Tiseo, Salvatore Siena, Roberto Labianca, Stefano Cascinu, Andrea Ardizzoni, Cesare Gridelli, Francesco Grossi, Lucio Crinò, Brunello Valentino, Franco Vito Piantedosi, Alessandra Bearz

Publikováno v: Lung cancer (Amsterdam, Netherlands). 64(2)

Background: Erlotinib demonstrated significantly prolonged survival versus placebo in patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST is a phase IV trial initiated to provide erlotinib access to patients with advanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65910c14635918b77b257e11c65ae75b
https://pubmed.ncbi.nlm.nih.gov/18951651

Zobrazit plný text záznamu

Ceftriaxone versus Other Antibiotics for Surgical Prophylaxis : A Meta-Analysis

Autor: Silvano Esposito, Paola Venturino, Alessandro Vanasia, Silvana Noviello

Publikováno v: Clinical drug investigation. 24(1)

To investigate possible differences in prophylaxis with ceftriaxone compared with other antimicrobial agents for surgical-site infections and remote infections such as respiratory tract infections (RTIs) and urinary tract infections (UTIs).The effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e035b01ee21b272117d2f6d981a0dc4
https://pubmed.ncbi.nlm.nih.gov/17516688

Zobrazit plný text záznamu

A Phase II Study of Combination Chemotherapy in Advanced Ovarian Carcinoma with Cisplatin and Cyclophosphamide plus Reduced Glutathione as Potential Protective Agent against Cisplatin Toxicity

Autor: Maria Cristina Locatelli, Adelaide D'Antona, Antonello Corbo, Paola Venturino, Michele Tedeschi, Gino Luporini, Rosario Carcione, Roberto Labianca, Maria Vinci

Publikováno v: Tumori Journal. 79:37-39

Aims and Backgroud The clinical use of cisplatin (CDDP)„ one of the most active agents in advanced ovarian cancer, is limited by nephrotoxicity and cumulative neurotoxicity. In preclinical studies, reduced glutathione (GSH) demonstrated a protectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f31f01ec664ce4cb8a4953c6c215e7da
https://doi.org/10.1177/030089169307900108

Zobrazit plný text záznamu

Adjuvant Radiotherapy of the Pelvis with or without Reduced Glutathione: A Randomized Trial in Patients Operated on for Endometrial Cancer

Autor: Anna Maria Falchi, Paola Venturino, Dario De Maria

Publikováno v: Tumori Journal. 78:374-376

A randomized pilot trial was performed to evaluate the feasibility of administration of glutathione (GSH, 1200 mg, i.v.) as a protector in preventing diarrhea in patients operated on for endometrial cancer and submitted to adjuvant radiotherapy of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9657552749f828afba489455463276d4
https://doi.org/10.1177/030089169207800605

Zobrazit plný text záznamu

Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger

Autor: Lucio Crinò, Ariela Brandes, Antonio Marchetti, Antonio Chella, Armando Santoro, Fausto Barbieri, Tommaso De Pas, Paola Venturino, Michele Milella

Publikováno v: Publons

e19020 Background: Patients (pts) with advanced NSCLC and activating mutations of EGFR represent a biologically distinct disease that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (TKIs) as ERL, demonstrated in phase III randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3b0ebae5e1071537f355a3d6d8c945
https://doi.org/10.1200/jco.2013.31.15_suppl.e19020

Zobrazit plný text záznamu

The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line

Autor: Francesco Grossi, G. Dal Bello, Carlo Genova, Giulia Barletta, Claudio Sini, Giovanni L. Pappagallo, E. Rijavec, Paolo Pronzato, Paola Venturino

Publikováno v: Publons

7577 Background: SD has often been viewed as a result with an uncertain clinical value.With the advent of E in advanced NSCLC, increasing numbers of patients (pts) achieve SD as a best response. A common observation in clinical practice is that a hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3406f0c55745f19ff90905662d24c07
https://doi.org/10.1200/jco.2012.30.15_suppl.7577

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání